Fully human single-domain antibodies against SARS-CoV-2
Yanling Wu(Shanghai Medical College of Fudan University), Tianlei Ying(Shanghai Medical College of Fudan University), Shibo Jiang(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Chao Tu(Central South University), Zhi Wang(Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Youhua Xie(Shanghai Medical College of Fudan University), Yu Kong(Fudan University), Chenjian Gu(Washington University in St. Louis), Rong Zhang(Guangxi University), Cheng Li(Shanghai Medical College of Fudan University), Xiaolong Tian(Fudan University)
Cited by 14
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400